Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma
- Conditions
- LeukemiaLymphoma
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 1148
- Registration Number
- NCT00002757
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇬🇧Children's Hospital - Sheffield, Sheffield, England, United Kingdom
Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- III. Medizinische Klinik Mannheim
- Target Recruit Count
- 1000
- Registration Number
- NCT00025402
- Locations
- 🇩🇪
Tumorzentrum Berlin-Moabit, Berlin, Germany
🇩🇪Wenckebach - Krankenhaus, Berlin, Germany
🇩🇪Gemeinschaftspraxis Fuer Innere Medizin, Haematologie Und Internistische Onkologie, Ansbach, Germany
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-05-15
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 400
- Registration Number
- NCT00003215
- Locations
- 🇨🇭
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
🇨🇭Inselspital, Bern, Bern, Switzerland
🇨🇭Ratisches Kantons und Regionalspital, Chur, Switzerland
Combination Chemotherapy and Total-Body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-11-30
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00027547
- Locations
- 🇺🇸
Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States
🇩🇪Universitaet Leipzig, Leipzig, Germany
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2009-12-23
- Target Recruit Count
- 2000
- Registration Number
- NCT00004128
Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia
- Conditions
- Recurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaUntreated Adult Acute Lymphoblastic LeukemiaUntreated Adult Acute Myeloid Leukemia
- Interventions
- Other: pharmacological studyOther: laboratory procedure
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-10-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 53
- Registration Number
- NCT00016016
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia
- Conditions
- Recurrent Childhood Acute Lymphoblastic LeukemiaL2 Childhood Acute Lymphoblastic LeukemiaL1 Childhood Acute Lymphoblastic LeukemiaNon-T, Non-B Childhood Acute Lymphoblastic LeukemiaT-cell Childhood Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-10-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 126
- Registration Number
- NCT00049569
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-08-27
- Target Recruit Count
- 472
- Registration Number
- NCT00052299
- Locations
- 🇮🇹
Ospedale San Bortolo, Vicenza, Italy
🇳🇱Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands
🇦🇹A. oe. Krankenhaus der Barmherzigen Schwestern Kinderabteilung, Linz, Austria
S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 33
- Registration Number
- NCT00049179
- Locations
- 🇺🇸
Charles B. Eberhart Cancer Center at DeKalb Medical Center, Decatur, Georgia, United States
🇺🇸Kennestone Cancer Center at Wellstar Kennestone Hospital, Marietta, Georgia, United States
🇺🇸David C. Pratt Cancer Center at St. John's Mercy, St. Louis, Missouri, United States
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia
- Conditions
- Leukemia
- Interventions
- Biological: sargramostimProcedure: Allogeneic HCTDrug: gemtuzumab ozogamicin (GO)Procedure: Autologous HCT
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 657
- Registration Number
- NCT00049517
- Locations
- 🇺🇸
Community Medical Center, Missoula, Montana, United States
🇺🇸Penn State Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸Mercy and Unity Cancer Center at Mercy Hospital, Coon Rapids, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.